Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Semnur Pharmaceuticals ( (SMNR) ) has provided an update.
On September 22, 2025, Semnur Pharmaceuticals, Inc. completed its business combination with Semnur Inc., turning the latter into a wholly owned subsidiary after the SPAC’s domestication from the Cayman Islands to Delaware. As part of its financing strategy around that transaction, the company had arranged separate securities purchase agreements to sell common stock at $16.00 per share to JW Capital Securities Limited and to Biconomy PTE. Ltd., with the Biconomy deal structured to be funded in Bitcoin.
However, no shares were ever issued under either the PIPE agreement with JW Capital or the Semnur/Biconomy agreement, and on April 20, 2026, Semnur terminated both deals effective that same day. The cancellation of these planned equity financings removes two previously disclosed capital sources tied to the deSPAC transaction, potentially affecting the company’s near-term funding flexibility and altering expectations for dilution among existing shareholders.
More about Semnur Pharmaceuticals
Semnur Pharmaceuticals, Inc., formerly known as Denali Capital Acquisition Corp., operates as a publicly listed holding company with Semnur Inc. as its wholly owned subsidiary following a September 22, 2025 business combination and domestication from the Cayman Islands to Delaware. The company is active in capital markets transactions involving common stock issuances tied to strategic financing agreements.
Average Trading Volume: 139
Technical Sentiment Signal: Sell
Current Market Cap: $1.15B
For detailed information about SMNR stock, go to TipRanks’ Stock Analysis page.